Top 50 Medical Startup Investors in Switzerland (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Zürcher Kantonal Bank
VC Fund
|
20 | Switzerland, Germany, Japan | Seed, Series A | Health Care, Biotechnology, Medical Device | $1.2M–$13M |
|
Verve Ventures
VC Fund
|
13 | Switzerland, Germany, France | Series A, Seed, Series B | Health Care, Software, Biotechnology | $1.4M–$45M |
|
Foundation for Innovation and Technology (FIT)
VC Fund
|
11 | Switzerland, France, United States | Debt Financing, Grant, Seed | Health Care, Biotechnology, Artificial Intelligence | $13k–$1.2M |
|
SICTIC
VC Fund
|
8 | Switzerland, Germany, Tanzania | Seed, Pre-Seed | Software, Artificial Intelligence, Information Technology | $302k–$3M |
|
StartAngels Network
VC Fund
|
6 | Switzerland, Brazil | Seed, Series A, Series B | Medical, Health Care, Medical Device | $933k–$6.1M |
|
BioMedPartners
VC Fund
|
6 | Switzerland, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.9M–$83M |
|
BlueOcean Ventures
VC Fund
|
5 | Switzerland, India, France | Seed, Series A, Series B | Health Care, Medical, Personal Health | $1M–$20M |
|
Sofinnova Partners
VC Fund
|
5 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6.6M–$109M |
|
Swisscom Ventures
VC Fund
|
5 | Switzerland, United States, United Kingdom | Series B, Series A | Software, SaaS, Information Technology | $1.8M–$60M |
|
4FOX Ventures
VC Fund
|
5 | Switzerland | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $2.1M–$69M |
|
Bernina BioInvest
VC Fund
|
5 | Switzerland | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $1.7M–$65M |
|
Kickfund
VC Fund
|
5 | Switzerland, Germany | Seed, Pre-Seed, Convertible Note | Biotechnology, Manufacturing, Medical | $110k–$5.7M |
|
OrbiMed
VC Fund
|
4 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $10M–$151M |
|
Schroder Adveq
VC Fund
|
4 | Switzerland, United States, India | Series B, Series C, Series A | Biotechnology, Health Care, Therapeutics | $5.6M–$100M |
|
Sunstone Life Science Ventures
VC Fund
|
4 | Denmark, Sweden, Switzerland | Series A, Series B | Biotechnology, Health Care, Medical | $5.5M–$52M |
|
Versant Ventures
VC Fund
|
4 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.7M–$108M |
|
Eclosion SA
VC Fund
|
4 | Switzerland | Seed, Series C | Biotechnology, Pharmaceutical, Health Care | $1.6M–$28M |
|
GoBeyond
VC Fund
|
4 | Switzerland, Germany, United Kingdom | Seed, Series A | Information Technology, Medical, Software | $544k–$10M |
|
Polytech Ventures
VC Fund
|
4 | Switzerland, United States, Spain | Seed, Series A | Financial Services, FinTech, Software | $1M–$9.7M |
|
New Enterprise Associates
VC Fund
|
4 | United States, India, United Kingdom | Series A, Series B, Series C | Software, Health Care, Biotechnology | $5.4M–$103M |
|
Fongit Seed Invest
VC Fund
|
4 | Switzerland | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $1.2M–$3.7M |
|
Zühlke Ventures AG
VC Fund
|
4 | Switzerland, Sweden, United States | Series A, Seed, Series B | Health Care, Medical Device, Medical | $1.2M–$11M |
|
3wVentures
VC Fund
|
4 | Switzerland, Spain, Austria | Seed, Angel, Series A | Software, Health Care, Medical | $50k–$8M |
|
Alpana Ventures
VC Fund
|
3 | United States, Switzerland, Germany | Seed, Series A | Software, FinTech, Information Technology | $850k–$14M |
|
M Ventures
VC Fund
|
3 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Endeavour Vision
VC Fund
|
3 | United States, Switzerland, France | Series C, Series B, Series A | Health Care, Medical, Biotechnology | $2.1M–$115M |
|
Founderful
VC Fund
|
3 | Switzerland, United Kingdom, Canada | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $1.2M–$24M |
|
EIT Health
VC Fund
|
3 | United Kingdom, Spain, Ireland | Grant, Pre-Seed, Seed | Health Care, Medical Device, Medical | $22k–$1.6M |
|
Fuho Capital
VC Fund
|
3 | China, Switzerland | Series A, Angel, Series B | Health Care, Biotechnology, Medical | $425k–$44M |
|
VINCI CAPITAL
VC Fund
|
3 | Switzerland, Germany | Series A, Series B | Medical, Health Care, Biotechnology | $8.6M–$36M |
|
Index Ventures
VC Fund
|
3 | United States, United Kingdom, France | Series A, Series B, Seed | Software, E-Commerce, Internet | $1.4M–$100M |
|
Innosuisse
VC Fund
|
3 | Switzerland, United States, United Kingdom | Grant, Pre-Seed, Seed | Health Care, Biotechnology, Medical Device | $17k–$16M |
|
XtalPi
VC Fund
|
3 | China, United States, Japan | Series A, Seed, Angel | Biotechnology, Health Care, Pharmaceutical | $1.5M–$30M |
|
S2S Ventures
VC Fund
|
3 | Switzerland, Germany | Pre-Seed, Seed | Health Care, Artificial Intelligence, Manufacturing | $28k–$3.4M |
|
Inserm Transfert Initiative
VC Fund
|
3 | France, Switzerland, United States | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.1M–$60M |
|
Broadview Ventures
VC Fund
|
3 | United States, Switzerland, Canada | Series A, Seed, Series B | Health Care, Biotechnology, Medical Device | $1M–$45M |
|
Gilde Healthcare
VC Fund
|
3 | United States, The Netherlands, Germany | Series B, Series C, Series A | Health Care, Biotechnology, Medical | $8.8M–$135M |
|
EQT Life Sciences
VC Fund
|
3 | United States, The Netherlands, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6.9M–$165M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
2 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.3M–$50M |
|
Helvetica Capital
VC Fund
|
2 | Switzerland | Seed, Series A | Medical, Computer, Biotechnology | |
|
Lichtsteiner Foundation
VC Fund
|
2 | Switzerland | Seed, Series A | Biotechnology, Health Care, Medical | $1.6M–$6.8M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
2 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $1.1M–$33M |
|
Penny Schiffer
Angel
|
2 | Switzerland, Germany, United Kingdom | Seed, Series A | Medical, Health Care, Finance | $544k–$9.3M |
|
ETH Zurich Foundation
VC Fund
|
2 | Switzerland | Seed, Pre-Seed, Grant | Information Technology, Medical, Software | $162k–$5.8M |
|
The William K. Warren Foundation
VC Fund
|
2 | United States, Switzerland | Seed, Series A, Series B | Machine Learning, Health Care, Artificial Intelligence | |
|
ORTHO INNOVATIONS
VC Fund
|
2 | Switzerland | Seed | Medical, Health Care, Biotechnology | |
|
Healthspan Capital
VC Fund
|
2 | Germany, Switzerland, United States | Seed | Health Care, Biotechnology, Medical | |
|
Calm/Storm Ventures
VC Fund
|
2 | United Kingdom, Germany, Austria | Seed, Pre-Seed, Series A | Health Care, Wellness, Software | |
|
Novartis Venture Fund
VC Fund
|
2 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | |
|
Grazia Equity
VC Fund
|
2 | Germany, United States, Switzerland | Series A, Series B, Seed | Internet, E-Commerce, Biotechnology | |
| Access all 481 investors in Switzerland Medical startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A
- Geography: Switzerland, Germany, Japan
Investor stats
- Total investments: 195
- Round size: Seed $1.2M–$6M; Series A $2.3M–$13M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Riverkin — Riverkin builds rugged, low-cost water sensor systems for rivers that measure turbidity and temperature in real time. Our platform turns field data into clear insights and decision making tools.
- QualySense — QualySense is a Swiss start-up company focused on innovative high-throughput grain, beans and seeds sorting technology. QualySense develops a high-speed multi-tons per hour sorting device, which will change how grains, beans and seeds are processed and valued worldwide by assessing the biochemical quality of grains one by one. The QualySensesorters will enable customers to separate grain batches into different biochemical quality classes and sell the corresponding premium products at higher average prices. Food processors will be able to considerably increase the production value, and produce higher quality products in a non-interrupted process.
- Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 273
- Round size: Seed $1.4M–$12M; Series A $2.6M–$18M; Series B $4.2M–$45M
- Lead/follow: 14% lead, 86% follow
- Last fund: Likely still investing — raised $66M in 2022
Portfolio highlights
- Kiutra — We provide cryogen-free cooling systems that simplify low-temperature research. Our solutions offer fast cooldowns, automated control and millikelvin performance ideal for quantum technologies and material science.
- Sleepiz — Sleepiz is a Zürich based startup with the aim to enable the medical community to take healthcare into the home environment. Sleepiz provides an easy and comfortable to use solution with a device that is simply placed on the bedside table. The device operates in a non-contact fashion and measures movements originating from heart contractions andbreathing patterns as well as body motions with medical grade accuracy.By making use of wireless millimeter wave technology, sensor fusion and artificial intelligence Sleepiz will in the future not only able to diagnose sleep disorders, but also to perform long-term monitoring. Thereby, the progression of chronic diseases can be monitored to allow faster intervention and better treatment.
- Clinpal — Backed by over 30 years of scientific discovery and validation, Cambridge Cognition offers the end-to-end platform for CNS clinical trials.
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Artificial Intelligence
- Stage:Debt Financing, Grant, Seed
- Geography: Switzerland, France, United States
Investor stats
- Total investments: 190
- Round size: Seed $117k–$1.2M; Grant $13k–$125k; Debt Financing $107k–$583k
- Lead/follow: 93% lead, 7% follow
Portfolio highlights
- Phonemia — Phonemia is a digital health company that offers artificial intelligence and speech therapy services.
- EM Path Tech — EM Path offers a cutting-edge radio frequency testing solution that caters to the needs of antenna and wireless system providers across diverse industry sectors. Our clients include Consumer Electronics, Antenna Component Providers, Automotive Radar Manufacturers, Radio Telescope Facilities, and Satellite Communication Companies. Our innovativesolution excels in streamlined data acquisition, eliminating the necessity for laborious point-to-point scanning of antennas. This not only enhances efficiency but also provides a competitive edge in the market. EM Path received supports from HEIG-VD, FIT, Venture Competition, VentureKick and Innosuisse.
- DiverSsiTy SA — DiverSsiTy SA develops personalized, patient-centric digital health technologies (DHTs) to improve the lives of patients suffering from neurodevelopmental disorders (NDDs), among which are those with autism spectrum disorder (ASD) and related comorbidities like attention-deficit/hyperactivity disorder (ADHD).
SICTIC is the leading angel investor network in Switzerland with the largest Swiss seed-stage startup dealflow.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Switzerland, Germany, Tanzania
Investor stats
- Total investments: 210
- Round size: Seed $583k–$3M; Pre-Seed $302k–$2.1M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Agrinorm — Agrinorm is a Swiss deep tech company leveraging cutting edge machine learning techniques for the optimization of fruits and veg supply chains.
- hypt — hypt is a Swiss based SaaS marketing solution that empowers companies to digitalize word-of-mouth. By using our word-of-mouth manager companies are able to activate 40% of their customers to send out a personal recommendation to their peers increasing sales through word-of-mouth by 4 times. Our solution empowers our ICP customers in the finance andinsurance segments to strategically use and optimize the most authentic and cost effective advertising channel – word-of-mouth – and makes it an accessible asset of every marketing mix.
- Get More Brain — Digital learning platform connecting learners and their employers with teachers and schools, publishers and EdTech companies. Marketplace for learning content and learning related services.
StartAngels Network is a Zurich-based angel investment firm that provides investment consulting services.
Show more...Investment focus
- Industry: Medical, Health Care, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Switzerland, Brazil
Investor stats
- Total investments: 27
- Round size: Seed $933k–$3.7M; Series A $2.1M–$3.7M; Series B $1.7M–$6.1M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Calingo — Calingo is a digital insurance platform that offers personalised and optimised risk protection at the point of sale.
- Scanvio — Scanvio Medical provides gynecologists, endometriosis centers and ultrasound manufacturers with an AI-guided ultrasound software for faster endometriosis diagnosis.
- Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 87
- Round size: Series A $5.5M–$31M; Series B $4.9M–$83M; Series C $5.8M–$48M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $113M in 2018
Portfolio highlights
- T-CURX — T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designedto improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care.
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
Show more...Investment focus
- Industry: Health Care, Medical, Personal Health
- Stage:Seed, Series A, Series B
- Geography: Switzerland, India, France
Investor stats
- Total investments: 17
- Round size: Seed $1M–$3M; Series A $2.3M–$20M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Augurix — Just another WordPress site
- Mikajaki — Mikajaki is an innovative automated multi-patient ocular diagnostics platform. The platform enables the use of digital technology, robots, AI, and data, allowing patients and eye specialists access to the specific treatment they require. Mikajaki is currently collaborating with ophthalmology clinic groups across the world to test and implementEyeLib.
- official.fm — At Official.fm, they develop powerful music promotion tools for you, whether you're an emerging artist or an accomplished label.They make it easy to manage a few tracks or a large catalog, create pages and players that look like you and share them across your favorite promotion platforms and social networks, all the while collectinginsightful analytics. Improving your workflow is their top priority.Promoting your music with official.fm will always be free. Music promotion is an investment for you and it is one for us too. Now you also have the ability to sell directly music to your fans. Soon they will offer more ways for your to generate revenue from your music.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 317
- Round size: Series A $6.6M–$65M; Series B $10M–$109M; Series C $12M–$100M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
- Comet Biorefining — Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosicglucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
- Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.
Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Series B, Series A
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 143
- Round size: Series A $1.8M–$23M; Series B $2.3M–$60M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- Apono — Apono makes permission management to applications, infrastructure, and data repositories simple, secure and compliant.
- Billogram — Since its start in 2011, Billogram has revitalized the outdated invoicing process by offering companies with recurring payments an intelligent digital platform. Using smart technology, we help companies strengthen their customer relations while also automating payment processes in a way that lowers costs, increases revenue, and reduces churn. Theresult is a payment that pays off for everyone.
- Bring! Labs — Bring! Labs is an app for multi-device use that accompanies the user through all aspects of shopping for groceries and other everyday items. It offers grocery shopping for millions of people with shared shopping lists, integrated recipes, online shopping, local offers, and loyalty cards. Bring! Labs offers innovative mobile advertising platforms tocompanies in the retail and FMCG.
4FO Ventures
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland
Investor stats
- Total investments: 20
- Round size: Seed $2.1M–$3.6M; Series A $2.1M–$15M; Series B $6.4M–$69M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
- Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
- Neo Medical — Neo aims at transforming the current approach to spinal surgery by providing a unique answer to the worldwide strive for healthcare cost optimization through efficient, versatile and high quality systems.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Bernina BioInvest is an investment Firm.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 11
- Round size: Seed $1.7M–$20M; Series A $17M–$65M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Versameb — Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Kickfund is a Venture Capital fund that systematically backs companies that successfully complete Venture Kick.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Medical
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: Switzerland, Germany
Investor stats
- Total investments: 47
- Round size: Seed $1.1M–$5.7M; Pre-Seed $335k–$4.4M; Convertible Note $110k–$118k
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- SolidWatts — We electrify industrial process heating by creating the new state-of-the-art in microwave and radio frequency power sources for industry.
- Cosaic — Cultivated - Creamy, dairy-free indulgence
- BLEEDnFIRE Therapeutics — BLEEDnFIRE Therapeutics: At BLEEDnFIRE Therapeutics, we are pioneering innovative siRNA-based therapies for hemophilia, Von Willebrand disease & other rare bleeding disorders (RBDs) by developing BnF-001. Our mission is to transform patient care and improve quand improve quality of life through targeted ...
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 611
- Round size: Series A $10M–$140M; Series B $24M–$151M; Series C $15M–$131M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- MDClone — The MDClone ADAMS Platform is a self-service, data analytics environment powering healthcare collaboration, innovation, and data-driven projects.
- Beijing Tianxing — Beijing Tianxing is a clinical solutions company for sports medicine for implants, arthroscopy devices, and sports medicine equipment.
- Aspen Neuroscience — personalized cell therapy Starts with you Learn More about our technology
Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Series A
- Geography: Switzerland, United States, India
Investor stats
- Total investments: 36
- Round size: Series A $5.6M–$23M; Series B $11M–$83M; Series C $15M–$100M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — raised $113M in 2020
Portfolio highlights
- Bizongo — Bizongo is a Tech-Enabled B2B Platform for Packaging, Apparels & Other Customised Goods. We digitally transform vendor management & supply chain.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 60
- Round size: Series A $5.5M–$43M; Series B $9.6M–$52M
- Lead/follow: 17% lead, 83% follow
- Last fund: May invest from a new fund soon — raised $94M in 2019
Portfolio highlights
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- Resalis Therapeutics — Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 287
- Round size: Series A $4.7M–$84M; Series B $10M–$105M; Series C $12M–$108M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Graphite Bio — Graphite Bio is a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases
- Lycia Therapeutics — Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.
- Nested Therapeutics — Nested Therapeutics is a Cambridge-based VC-backed stealth biotech company. The company's focus is on finding and creating new precision oncology small-molecule drugs targeted toward cancer genes. Nested Therapeutics was established in 2021 in Cambridge, Massachusetts.
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Seed, Series C
- Geography: Switzerland
Investor stats
- Total investments: 16
- Round size: Seed $1.6M–$2.7M; Series C $20M–$28M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
- Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
- MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more...Investment focus
- Industry: Information Technology, Medical, Software
- Stage:Seed, Series A
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 163
- Round size: Seed $544k–$5M; Series A $1.2M–$10M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Fastree3D — Fastree3D imaging sensors help recognize and measure distance to fast moving objects in real-time, enabling driving assistance or autonomous navigation. Fastree3D SA is a fabless semiconductor company, spin-off from EPFL Lausanne, Switzerland founded in September 2013 (UID CHE-291.330.490). The company subsidiary Fastree3D B.V. performs researchwith TU-Delft, Netherlands (KvK 58866973).
- Spyra One — Single Shot Technology | Tactical display | Automatic Refill | Power Shot SpyraTwo - the world's strongest water gun! Start epic water battles with the only water gun in the world that features our patented Single-Shot-Technology, fully automatical pump, a hightech tactical display and the Power Shot for extra impact.
- DomoHealth — Join us in revolutionizing patient care using the power of AI-assisted digital health platform and safety solutions. Enhancing digital health with the best platform, application and devices for the direct benefits of patients and healthcare professionals.
Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world
Show more...Investment focus
- Industry: Financial Services, FinTech, Software
- Stage:Seed, Series A
- Geography: Switzerland, United States, Spain
Investor stats
- Total investments: 50
- Round size: Seed $1M–$5M; Series A $2.3M–$9.7M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $40M in 2016
Portfolio highlights
- Relai — All you need to get started is to download our award winning Relai app, complete a simple verification and start buying with as little as 50 CHF/EUR.
- Hemostod — Developing universal platelets and next-generation diagnostics
- Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
Foundational partners to ambitious founders at every stage of company-building.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1581
- Round size: Series A $5.4M–$60M; Series B $10M–$77M; Series C $14M–$103M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $2.8B in 2022
Portfolio highlights
- IonQ — Working to build the world's best quantum computers to solve the world's most complex problems
- Spyglass Ophthalmics — A vision towards a higher quality of life!
- Xenon Pharmaceuticals — A leading neuroscience company forging new paths for those living with neurological and psychiatric disorders.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 9
- Round size: Seed $1.2M–$1.4M; Series A $2.3M–$3.7M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
Zühlke Ventures AG is a venture capital arm of Zühlke Technology Group AG specializing in financing of start-ups at an early stage and providing growth capital. It seeks to invest in the technology and medical devices companies. It typically invests in German-speaking Europe and Great Britain.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Sweden, United States
Investor stats
- Total investments: 12
- Round size: Seed $1.2M–$3M; Series A $7M–$11M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Evismo — Diagnosing arrhythmias, sleep apnea, and stress directly in your practice. Digitally and efficiently. For general practitioners and specialists in Switzerland.
- Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
- PeriVision — At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
3wVentures provides seed money and venture capital to international internet startups. As they focus on early stage projects and prototypes, our investments and co-investments target a volume of up to USD 250,000.
Show more...Investment focus
- Industry: Software, Health Care, Medical
- Stage:Seed, Angel, Series A
- Geography: Switzerland, Spain, Austria
Investor stats
- Total investments: 42
- Round size: Seed $50k–$3.8M; Angel $583k–$2.1M; Series A $1.2M–$8M
- Lead/follow: 2% lead, 98% follow
- Last fund: May invest from a new fund soon — raised $100M in 1999
Portfolio highlights
- Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
- GUURU Solutions — Discover how community-powered advice can turn your PDPs into trusted, high-converting content and get cited in AI search.
- Pregnolia — Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete theclinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.
Alpana Ventures is a Swiss VC focusing on digital transformation.Since 2016 we backed 45 founder teams with 3 Funds, supporting them in their journey towards a positive impact.Committed to value creation, we discover deep tech solutions in Switzerland, Europe and the US.We invest to embed them into innovative business models and back them tobecome global market leaders.Applying ESG criteria, our portfolio companies help create a more sustainable future.
Show more...Investment focus
- Industry: Software, FinTech, Information Technology
- Stage:Seed, Series A
- Geography: United States, Switzerland, Germany
Investor stats
- Total investments: 98
- Round size: Seed $850k–$4M; Series A $2.3M–$14M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
- Nezasa — Discover how to grow your business with Nezasa TripBuilder, the world's leading travel commerce solution for travel businesses.
- Tinamu — Trusted inventory intelligence delivered in real-time
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 170
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
- ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
Endeavour Vision is an investment advisory firm focused on transformative healthcare technologies.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series C, Series B, Series A
- Geography: United States, Switzerland, France
Investor stats
- Total investments: 70
- Round size: Series A $2.1M–$30M; Series B $7M–$45M; Series C $12M–$115M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $375M in 2021
Portfolio highlights
- Nalu Medical — Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
- Venture Med Group — Create a dynamic website for your electrical services with Avada & WordPress. Showcase your expertise, services, and attract clients with engaging designs.
- Kestra Medical Technologies, Inc. — Kestra Medical Technologies is a wearable medical device and digital healthcare company that protects patients with diagnostic and therapeutic technologies that are intuitive, and mobile. They provide intuitive medical technologies to protect and support at-risk patients.
Founderful operates as a venture capital firm and a Switzerland’s leading pre-seed fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Switzerland, United Kingdom, Canada
Investor stats
- Total investments: 101
- Round size: Seed $1.5M–$16M; Pre-Seed $1.2M–$3.8M; Series A $3.4M–$24M
- Lead/follow: 55% lead, 45% follow
- Last fund: Likely still investing — raised $85M in 2024
Portfolio highlights
- AVIAN —
- Calvin Risk — We help companies manage the risks of their AI algorithms!
- Stellar Alpina — Stellar Alpina is a Zurich-based space propulsion startup developing rotating detonation rocket engines for mobility after launch.
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Grant, Pre-Seed, Seed
- Geography: United Kingdom, Spain, Ireland
Investor stats
- Total investments: 97
- Round size: Seed $220k–$1.4M; Grant $22k–$1.6M; Pre-Seed $44k–$1.4M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- IDOVEN — IDoven develops products to detect heart problems at an early stage to prevent heart diseases.
- Noah Labs — A breakthrough for heart failure: Noah Labs Ark is a Class IIa Medical Device Software with AI-driven detection of early cardiac decompensation through voice.
- Trak — Trak is a software tool for healthcare professional to provide AI-based tele-rehabilitation services like physiotherapy and others.
Fuho Capital is an equity investment fund management company.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Angel, Series B
- Geography: China, Switzerland
Investor stats
- Total investments: 32
- Round size: Angel $425k–$2.8M; Series A $709k–$29M; Series B $2.8M–$44M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Novamab — Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platformand a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc.
- Hexaell Biotech — Hexaell Biotechnology Co., Ltd is a start-up company pioneering in stem cell and artificial organ. The disruptive technologies were original published in "Nature. 475(7356):386-9" and "Cell Stem Cell. 14(3):370-84" from Chinese Academy of Sciences. Hexaell Biotechnology had licensed iHep and HiHep technologies from ChineseAcademy of Sciences and developed medical devices of bio-artificial liver to replace liver function of human and cure liver failure diseases. Hexaell has finished pilot clinical studies in 6 liver failure patients in leading hepatopathy centers in China.
- Mainstream Biotech — Mainstream Bio is a biotechnology company grounded in research, specializing in the development of innovative peptide therapeutics 2.0.
Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Series B
- Geography: Switzerland, Germany
Investor stats
- Total investments: 15
- Round size: Series A $8.6M–$20M; Series B $21M–$36M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $10M in 2012
Portfolio highlights
- Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
- SENSIMED — Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.
- Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.
Show more...Investment focus
- Industry: Software, E-Commerce, Internet
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 1170
- Round size: Seed $1.4M–$16M; Series A $5M–$35M; Series B $10M–$100M
- Lead/follow: 44% lead, 56% follow
- Last fund: May invest from a new fund soon — raised $117M in 2015
Portfolio highlights
- Codat — Codat turns on-demand client data into personalized insights that help commercial banking teams deepen relationships and grow revenue.
- StorSimple — Learn how to migrate a StorSimple 8100 or 8600 appliance to Azure File Sync.
- Trustpilot — Trustpilot is a powerful review platform - free and open to all. With more than 58 million reviews of over 270,000 domains, Trustpilot gives people a place to share and discover reviews of businesses, and we give every company the tools to turn consumer feedback into business results. Our mission is to bring people and businesses closer together tocreate ever-improving experiences for everyone. Trustpilot reviews are seen more than 3 billion times each month by consumers worldwide. With offices in Copenhagen, London, New York, Denver, Berlin, Melbourne and Vilnius, Trustpilot's 700 employees represent more than 40 different nationalities.
Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Grant, Pre-Seed, Seed
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 233
- Round size: Seed $500k–$16M; Grant $30k–$2.7M; Pre-Seed $17k–$4.3M
- Lead/follow: 79% lead, 21% follow
Portfolio highlights
- OrthoSens — OrthoSens develops battery-free sensors that turn standard orthopedic implants into smart, data-driven devices. Unlike existing smart implant solutions that require an implanted battery making them too large and too risky to scale beyond large joints, OrthoSens moves all electronics outside the body. A paper-thin sensor integrates directly intoexisting implants with no battery, no surgical workflow change and zero explant risk. An external wearable powers the sensor wirelessly and collects real-time data on load, micromotion and bone fusion. The result is a footprint 250x smaller than battery-powered competitors, opening up additional spine, foot & ankle markets that existing solutions cannot address. The clinical need is clear: approximately 20% of post-surgical patients drive around 68% of total post-operative costs through missed complications, continuous implant monitoring exists to catch them earlier. Starting January 2026, 745 US hospitals enrolled in CMS's mandatory TEAM bundle are now accountable for 30-day episode costs, creating direct institutional demand for this data.OrthoSens generates revenue through three streams: sensor sales to orthopedic implant manufacturers (unlocking +$1,309 NTAP reimbursement per unit), a SaaS subscription capturing 40% of Medicare's $104/month RPM reimbursement per patient and post-market data analytics. The company has validated its technology across 3 functional prototypes, filed 2 core patents with favorable Freedom to Operate and secured $1.3M+ in non-dilutive funding. It is raising a $2.3M seed round to complete ISO-13485 certification, conduct the FDA pre-clinical study and file a 510(k) submission. The team is led by Gwenael Hannema (3x medtech founder), Dr. Oleg Kotsur (Head of R&D), and key employees, supported by experienced board members with leadership backgrounds at Novartis, Medtronic and J&J MedTech.
- Chiral — Next-generation electronics with nanomaterials
- BLEEDnFIRE Therapeutics — BLEEDnFIRE Therapeutics: At BLEEDnFIRE Therapeutics, we are pioneering innovative siRNA-based therapies for hemophilia, Von Willebrand disease & other rare bleeding disorders (RBDs) by developing BnF-001. Our mission is to transform patient care and improve quand improve quality of life through targeted ...
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enablespharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide.Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Seed, Angel
- Geography: China, United States, Japan
Investor stats
- Total investments: 26
- Round size: Seed $1.5M–$15M; Series A $11M–$30M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- Rabbitpre — Rabbitpre is a big data-driven technology marketing company.
- Dingxi Zhichuang — Dingxi Zhichuang is an integrated circuit chip developer specializing in the manufacture, design, and services of integrated circuit chips and products, as well as sales and the manufacturing of semiconductor device special equipment.
- Xellar Biosystems — Xellar Biosystems is a wet artificial intelligence biotechnology company that provides analysis of drug testing and treatment.
S2S Ventures is a fully student-led VC fund from Switzerland, backed by some of the country's most successful entrepreneurs.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Manufacturing
- Stage:Pre-Seed, Seed
- Geography: Switzerland, Germany
Investor stats
- Total investments: 27
- Round size: Seed $954k–$3.4M; Pre-Seed $28k–$2.9M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely still investing — raised $13M in 2021
Portfolio highlights
- Haicker — Haicker is an AI-driven cybersecurity platform designed to automatically detect vulnerabilities in web application codebases with exceptional precision. Leveraging advanced Large Language Model (LLM)-based agents, Haicker outperforms traditional security testing solutions by removing false positives and providing actionable insights that helpdevelopers fix vulnerabilities swiftly and confidently.Traditional static (SAST) and dynamic (DAST) application security testing tools typically suffer from high rates of false positives, demanding significant manual review efforts from developers and security teams. Haicker addresses this core challenge through its unique architecture: all issues are validated against a replica of the application, allowing Haicker to filter real findings from hallucinations.Initially proven in competitive cybersecurity environments like Capture-the-Flag (CTF) competitions, Haicker quickly demonstrated superior performance and reliability on open source projects. Its capabilities extend beyond vulnerability scanning, integrating seamlessly into common development workflows, including continuous integration and delivery pipelines.Haicker's scalable architecture ensures enhanced performance as computational resources and AI models evolve and become more cost-effective. By leveraging a distributed approach where multiple AI agents concurrently analyze the same piece of code, Haicker ensures comprehensive vulnerability detection with unprecedented depth and efficiency.Targeted at security-conscious enterprises, software development teams, and DevSecOps practitioners, Haicker empowers organizations to shift security left, integrating deep vulnerability detection early into the development lifecycle. Its intuitive interface and streamlined integration capabilities with leading code management platforms such as GitHub, GitLab, and Bitbucket enable effortless adoption.Founded in Switzerland by cybersecurity and web development experts, Haicker is positioned to transform the application security market by offering a smarter, faster, and more reliable alternative to manual penetration tests and legacy automated scanning solutions.
- Scanvio — Scanvio Medical provides gynecologists, endometriosis centers and ultrasound manufacturers with an AI-guided ultrasound software for faster endometriosis diagnosis.
- Forgis — Forgis is leading the next industrial revolution by introducing industrial intelligence into factories, which boosts the competitiveness of Western manufacturing.
Inserm Transfert Initiative is a seed stage life science vehicle currently managing about €4.2M for the financing of new biotech companies. Inserm Transfert Initiative is the new investment vehicle of INSERM in France.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: France, Switzerland, United States
Investor stats
- Total investments: 22
- Round size: Seed $2.7M–$3.6M; Series A $1.1M–$35M; Series B $2.2M–$60M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Eyevensys — Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
- VectivBio — Explore Ironwood Pharmaceuticals' commitment to GI health with innovative therapies, patient-focused research, and a vision to improve digestive disease treatment.
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Seed, Series B
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 78
- Round size: Seed $1M–$9.5M; Series A $1M–$30M; Series B $7M–$45M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Adient Medical — Medical Devices that Automatically Vanish - Adient Medical is leading the development of an absorbable vascular filter for the prevention of pulmonary embolism.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Mosanna Therapeutics — Mosanna is a Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, The Netherlands, Germany
Investor stats
- Total investments: 130
- Round size: Series A $8.8M–$65M; Series B $15M–$135M; Series C $21M–$75M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $786M in 2023
Portfolio highlights
- Big Health — Our mission is to help millions back to good mental health. Our digital therapeutics are safe and effective non-drug alternatives for mental health.
- GT Medical Technologies — GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes.
- Endovascular Engineering — Endovascular Engineering is a preclinical stage company developing novel mechanical thrombectomy solutions to address peripheral indications.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, The Netherlands, Switzerland
Investor stats
- Total investments: 182
- Round size: Series A $6.9M–$77M; Series B $12M–$110M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $266M in 2023
Portfolio highlights
- LUMA Vision — OneProjects is an Irish-German cardiac imaging specialist.
- Neurent Medical — Discover NEUROMARK, a minimally invasive solution for Chronic Rhinitis that targets the posterior nasal nerve to provide lasting symptom relief.
- Rotation Medical — Rotation Medical Inc. manufactures and markets a collagen scaffold for rotational cuff disease in Minnesota. The company was formerly known as Denali Medical Inc. and changed its name to Rotation Medical Inc. in March 2010. Rotation Medical was founded in 2009 and headquartered in Plymouth, Minnesota.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 96
- Round size: Seed $1.3M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
- ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
- Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
Helvetica Capital is an independent, entrepreneurial investor focusing on Swiss companies.
Show more...Investment focus
- Industry: Medical, Computer, Biotechnology
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 2
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Microcaps — Explore the ethanol-free fine fragrance solution. Perfume Pearls are a water-based perfume technology for your water-based perfume.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 10
- Round size: Seed $1.6M–$6.8M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Hemostod — Developing universal platelets and next-generation diagnostics
- DigeHealth — DigeHealth's approach to monitoring gut health using bowel noises and body measurements could provide some really valuable insights into digestive well-being.
- Allegria Therapeutics — Allegria Therapeutics operates as a biotech company.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 583
- Round size: Seed $1.1M–$7.3M; Series A $3.5M–$33M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- DcubeD — Accelerate your space exploration through durable and affordable Release Actuators, Solar Arrays, and Deployables from DCUBED.
- FINE Legal — fine. holt Dir Dein Geld einfach, digital und ohne Risiko.
- NAVAN Technologies — NAVAN Technologies, Inc., (NAVAN) is a pre-clinical stage biotechnology company developing and commercializing its proprietary NanoStraw platform technology, which establishes a direct, physical connection into cells to overcome a huge challenge faced by researchers globally: delivering material into hard-to-transfect-cells in an efficient yetgentle and non-perturbative manne
Penny Schiffer - CEO & Co-founder @ Raized.ai
Show more...Investment focus
- Industry: Medical, Health Care, Finance
- Stage:Seed, Series A
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 34
- Round size: Seed $544k–$9.3M; Series A $1.2M–$7M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Versameb — Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
- Enterprise Bot — Cost-effective Conversational AI solutions transforming customer interaction for global enterprises. Discover cutting-edge chat, email, and voice tech.
- Scientific Visual — Scientific Visual supplies quality control workstations to visualize defects in non-polished sapphire such as watch covers, ingots and wafers.
ETH Zurich Foundation is an independent, non-profit-making foundation under private law for the promotion of education and research at ETH Zurich.
Show more...Investment focus
- Industry: Information Technology, Medical, Software
- Stage:Seed, Pre-Seed, Grant
- Geography: Switzerland
Investor stats
- Total investments: 21
- Round size: Seed $1.1M–$5.8M; Grant $162k–$175k; Pre-Seed $473k–$4.4M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- FenX — FenX is a recyclable insulating product that turns mineral waste into usable resources to support a circular economy. Real estate developers, construction companies, and architects can now access non-flammable insulation materials for construction processes. the company's portfolio of recyclable insulation materials, which includes foamproducts and foam formulations made from readily available waste or natural materials with CO2 emissions.
- Soverli —
- Tethys Robotics — Tethys Robotics develops AI-powered application oriented robotics system that enables professionals in carrying underwater search & recovery to inspection & surveillance.
The William K. Warren Foundation focuses on people and aims to improve the human condition on earth as a response to and in thanksgiving.The foundation's goal is to make medical care available to all patients utilizing Saint Francis Health System, and to this end, it annually supports various medical programs. In addition to the hospitalsand clinics, the foundation created The William K. Warren Medical Research Centre in 1973, which provides funds to medical investigators who participate in advanced medical research and creates environments that allow for the best possible delivery of care.
Show more...Investment focus
- Industry: Machine Learning, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Switzerland
Investor stats
- Total investments: 7
- Lead/follow: no public data
Portfolio highlights
- KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
- Spring Health — Eliminating barriers to mental healthcare. Clinically-proven technology with world-class providers to deliver precisely what your employees need.
- iRecommend Software™ — Play the best slots, exciting sports betting, and real-time live dealer games at Pin Up Casino India. Get your welcome package worth up to $5,000 plus 250 free spins and kick off your winning journey today!
Ortho Innovations is a manufacturer of orthopedic products. The company's products are the elbow brace, knee brace, hyperflexion elbow, wrist, flexion-extension, wrist pronation, supination, and hip abduction orthosis.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed
- Geography: Switzerland
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
Healthspan Capital is an early-stage longevity venture capital firm that invests in biotechnology startups developing therapies to slow or reverse aging.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 7
- Lead/follow: no public data
Portfolio highlights
- KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
- ImmuneAGE Bio — ImmuneAGE Bio is the first drug discovery platform company focused on immune system rejuvenation.
- Reservoir Neuroscience — Reservoir Neuroscience is a biopharma company that develops novel therapeutics to repair dysfunctional blood vessels in the brain. Reservoir Neuroscience was founded in 2019 and is based in Emeryville, California.
Calm/Storm is an exclusive founder network and venture capital firm. We invest in purpose driven founders changing our life & health for the better. Headquartered in Vienna, Austria we invest in early-stage companies all over Europe and the US. We focus on the pre-seed and seed stages but also invest up to Series A.
Show more...Investment focus
- Industry: Health Care, Wellness, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, Germany, Austria
Investor stats
- Total investments: 113
- Lead/follow: no public data
Portfolio highlights
- aiomics — Aiomics | Back to your calling.Across Europe, healthcare providers lose hours every day to fragmented documentation—handwritten notes, scanned PDFs, dictations, disconnected IT systems. The result: burnout, missed revenue, and patients feeling like they’re asked the same question three times.Aiomics changes this. Our AI-driven co-pilot capturesevery clinical detail—speech, handwriting, digital notes—and validates it in real time with a human-in-the-loop process. Interactive checklists surface missing information before the patient leaves, and audit-ready records flow straight back into existing systems. Built for GDPR, MDR, and the EU AI Act from day one, Aiomics makes documentation complete, compliant, and instantly usable.We don’t replace EHRs—we make them better. From admission and discharge reports to insurer forms, from therapist briefings to patient-friendly letters, Aiomics turns paperwork from a burden into an asset. For providers, that means fewer errors, faster reimbursements, and—most importantly—more time at the bedside.Our mission: to empower healthcare professionals by removing administrative burdens and elevating their decision-making with trusted AI guidance—so they can reconnect with why they chose this vocation in the first place.Who we are: Aiomics is co-founded by Dr. Sven Jungmann, a physician with frontline experience of administrative overload; Dr. Nikita Tarasov, a physicist and data scientist; and a lawyer who scaled one of Europe’s largest digital service companies. Together, we unite empathy, technical mastery, and regulatory expertise to build the trusted co-pilot for Europe’s healthcare providers.
- ThinkSono — ThinkSono is a company at the cutting edge of medicine and technology.
- Nolea Health — As a clinician with Nolea you can set your own schedule, work with as many healthcare companies as you want, hold all of your credentials in one single sharable wallet, access new educational resources, and receive community feedback.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 204
- Lead/follow: no public data
Portfolio highlights
- Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
- Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
- Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.
Show more...Investment focus
- Industry: Internet, E-Commerce, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: Germany, United States, Switzerland
Investor stats
- Total investments: 81
- Lead/follow: no public data
Portfolio highlights
- Q.ANT — Q.ANT develops photonic processors for AI and high-performance computing, utilizing light for information processing. The company also produces quantum sensors offering ultra-high magnetic field sensitivity in a compact form factor. These products aim to enable more intelligent and sustainable systems across various sectors like data centers,aerospace, and medical technology.
- Vytal — Start the Packaging Revolution! We are offering smart & reusable To-Go Packaging-as-a-Service to gastronomy clients & consumers.In Germany the consumption of take-away, convenience and delivery food & drinks is responsible for about 281 kilotons of single-use packaging waste for immediate consumption and is growing at double digitrates. Most of the time, To-Go food containers, snack boxes or coffee cups have a very short life-span of only 30 minutes after which they are tossed into trash (or litter parks, beaches & the ocean). This is not only a giant waste of economic resources as each single use costs between 15 and up to 0,60€ for a stable bowl/box with a lid. It is a horrendous waste of environmental resources (wood, water, crude oil, metals & energy) that are used to produce this packaging. Therefore, a single use packaging not weighing more than 30 grams can easily come with an ecological backpack of more than 8 kilograms when taking into account all the resources used in production (material intensities taken from Wuppertal Institute for Climate, Environment and Energy). Looking at GHG emissions, the picture is similarly bleak: Using CO2 emission factors and the detailed material mix of the single-use packaging waste analyzed by NABU (German Nature and Biodiversity Conservation Union), the 281 thousand tons waste from To-Go consumption generated around 556 thousand tons of CO2 or the equivalent of 195k passenger cars per year (assuming an average distance travelled of 15,000km). With the expected rise of take-away, convenience and delivery food, the related emissions are expected to increase at double digit rates as waste volume is expected to increase and as we saw a shift to plastics relative to cardboard or other materials. While there is a growing awareness of the problem, especially in Germany, there is no scalable solution yet and the commonly used alternative of nature-based & ‘biodegradable’ materials like bagasse or PLA also require many resources for production & transport, and have to be incinerated or go to landfill after use as there is currently no way to compost them.
- Lumotive — Lumotive is a Seattle-based startup company developing high performance, solid-state lidar for autonomous systems in the automotive, UAV, robotics and related industries. The company's revolutionary beam-steering technology leverages Liquid Crystal Metasurfaces (or LCMs) implemented in mature semiconductor manufacturing processes to deliversmall, inexpensive 3D perception systems with unprecedented performance and reliability. For more information, visit us at www.lumotive.com.
Medical Investor funding in Switzerland at a glance
Stats across 508 deals from 481 investors.
Access all 481 investors in Switzerland Medical startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical Investors in Switzerland investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 481 investors investing in Switzerland Medical startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!